News | April 07, 2008

Bi-Atrial Lesion Pattern Produces Positive Positive Results in Afib Patients

April 8, 2008 - Atrial fibrillation demonstrated that a port access, paracardioscopic Ex-Maze procedure produced favorable outcomes and allowed patients to discontinue antiarrhythmic drugs, according to interim results from a study presented by Andy C. Kiser, M.D., at the American College of Cardiology meeting in Chicago, IL.

Epicardial lesions to complete the bi-atrial pattern were created in all patients by coagulating cardiac tissue using the nContact Surgical VisiTrax device.

The 37 patients reported in the study had an average age of 61 years, a mean duration of atrial fibrillation of 7.4 years, and a mean left atrial size of 5.7 cm. Seventy-eight percent of the patients had long-standing persistent atrial fibrillation. Analysis of three-month interim outcomes demonstrated normal sinus rhythm in 17/20 (85 percent) patients. For those patients who had reached six months, 7/7 (100 percent) patients experienced normal sinus rhythm without antiarrhythmic drugs.

"This is a truly minimally invasive approach that treats both the left and right atrium without the use of cardiopulmonary bypass,"? stated Dr. Kiser. "These interim closed-chest results are very promising, particularly, when intra-operative metrics, including spontaneous conversion to normal sinus rhythm and confirmed exit block, are met."

For more information: www.Ex-Maze.com and www.ncontactsurgical.com

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Overlay Init